TOG Review (RCOG Journal)

MRCOG Part 2

Gynaecological Oncology

Paraneoplastic syndrome associated with gynaecological malignancy

Key Statistics

  • ~8% — PNS incidence, all oncology patients
  • 23% — Anti-yo positive in ovarian carcinoma
  • 22 yrs — Median age, NMDAR-antibody encephalitis

Don't-miss facts

  1. PNS symptoms often pre-date the cancer diagnosis – treat as a red flag for occult malignancy work-up

  2. Anti-Yo PCD: 23% of ovarian carcinoma patients positive; do NOT serially monitor antibody titres (no correlation with severity); median survival 22 months

  3. NMDAR encephalitis: median age 22; 65% have an ovarian teratoma – arrange pelvic ultrasound surveillance; immunotherapy >75% good outcome

  4. Paraneoplastic hypercalcaemia = ectopic PTHrP, normal-to-low PTH; treat with fluids first, then bisphosphonates

  5. SCCOHT: young women, SMARCA4 mutation, <1% of ovarian cancers, poor prognosis, usually hypercalcaemic

  6. Struma ovarii surgery risks thyroid storm – antithyroid drugs + laparoscopic approach + careful monitoring

  7. GTD hyperthyroidism driven by very high hCG (4000× less potent than TSH at receptor) – resolves with choriocarcinoma treatment

  8. FIGO GTN score ≤6 = low risk, ≥7 = high risk of resistance to chemotherapy

PNS by system – quick map

Neuro: PCD (anti-Yo), encephalitis (anti-Hu, NMDAR) Endocrine: Cushing's, hypercalcaemia, hyperthyroidism

Rheum: dermatomyositis (ovarian cancer, 25%)

Abbreviation Key

  • PNS — paraneoplastic syndrome
  • PTH — parathyroid hormone
  • PCD — paraneoplastic cerebellar degeneration
  • SCCOHT — small cell carcinoma of the ovary, hypercalcaemic type
  • NMDAR — N-methyl-D-aspartate receptor
  • hCG — human chorionic gonadotrophin
  • CDR2 — cerebellar degeneration-related protein 2
  • TSH — thyroid-stimulating hormone
  • MRI — magnetic resonance imaging
  • GTD — gestational trophoblastic disease
  • ACTH — adrenocorticotrophic hormone
  • GTN — gestational trophoblastic neoplasia
  • CRH — corticotrophin-releasing hormone
  • FIGO — International Federation of Gynecology and Obstetrics
  • PTHrP — parathyroid hormone-related protein
  • IVIg — intravenous immunoglobulin

Source: Brown A et al. Paraneoplastic syndrome associated with gynaecological malignancy: a review of the evidence. The Obstetrician & Gynaecologist 2022;24:137–142. doi:10.1111/tog.12804

MRCOG AI is an independent educational tool. It is not affiliated with, endorsed by, or connected to the Royal College of Obstetricians and Gynaecologists (RCOG).

Included with a Pass Package

  • Audio overview of this guideline
  • Practice questions drawn from it
  • AI tutor answers grounded in its text
  • Your own annotations
Start free